Nivolumab
- CAS No.
- 946414-94-4
- Chemical Name:
- Nivolumab
- Synonyms
- Opdivo;ONO 4538;MDX 1106;Nivolumab;BMS 936558;Nivolumab 10mg/ml;Nivolumab USP/EP/BP;Nivolumab (anti-PD-1);Research Grade Nivolumab(DHH02209)
- CBNumber:
- CB42738187
- Molecular Formula:
- Molecular Weight:
- 0
- MDL Number:
- MOL File:
- Mol file
| storage temp. | Store at -80°C |
|---|---|
| NCI Dictionary of Cancer Terms | nivolumab; Opdivo |
| FDA UNII | 31YO63LBSN |
| NCI Drug Dictionary | nivolumab |
| ATC code | L01XC17 |
Nivolumab price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| American Custom Chemicals Corporation | API0018408 | ONO-4538 95.00% | 946414-94-4 | 5MG | $498.36 | 2021-12-16 | Buy |
| ChemScene | CS-7489 | Nivolumab 98.56% | 946414-94-4 | 5mg | $670 | 2021-12-16 | Buy |
| Biosynth Carbosynth | BN164047 | Nivolumab | 946414-94-4 | 5mg | $825 | 2021-12-16 | Buy |
| Biosynth Carbosynth | BN164047 | Nivolumab | 946414-94-4 | 10mg | $1500 | 2021-12-16 | Buy |
| ChemScene | CS-7489 | Nivolumab 98.56% | 946414-94-4 | 1mg | $280 | 2021-12-16 | Buy |
Nivolumab Chemical Properties,Uses,Production
Mechanism of action
Nivolumab is a fully human, monoclonal IgG4 antibody that binds to programmed death-1 (PD-1) receptors with high specificity and affinity. PD-1 is expressed on T cells and dampens their immune response upon binding ligands PD-L1 and PD-L2 on APCs. This mechanism is pivotal to regulating central and peripheral tolerance. In cancer, aberrant PD-L1 expression by tumor cells or immune cells in the tumor microenvironment deactivates PD-1, expressing tumor-infiltrating lymphocytes, thereby allowing tumor cells to escape immune recognition and elimination. By inhibiting PD-1 function, nivolumab releases immune cells from pathological immune suppression, allowing them to recognize and counter tumor cells.
Clinical Use
Monoclonal antibody:
Treatment of advanced (unresectable or metastatic)
melanoma, non-small cell lung cancer, renal cell
carcinoma, classical Hodgkin lymphoma, squamous
cell cancer of the head and neck and urothelial
carcinoma
Side effects
The most common Immune-related adverse events (iRAEs) affect systems include the gastrointestinal and integumentary systems, usually manifesting as a pruritic rash, diarrhea, or colitis. When immune-mediated endocrine inflammation subdues, glandular function may be compromised, thus necessitating permanent hormone substitution. This includes nivolumab-induced hypothyroidism, hypopituitarism, adrenal insufficiency, and diabetes mellitus type 1.
Immune-mediated pneumonitis is a rare adverse effect associated with severe manifestations. Immune-related myocarditis is a very uncommon adverse event with high lethality. Less common adverse effects include ocular (uveitis, conjunctivitis, myositis of periocular muscles), inflammatory hepatitis, endocrinopathies such as hypothyroidism, hypopituitarism, and adrenal insufficiency. Other rare adverse events include those affecting the neurological system (encephalitis, Guillain-Barré syndrome).
Drug interactions
Potentially hazardous interactions with other drugs
Live vaccines: avoid concomitant use
Metabolism
The metabolic pathway of nivolumab has not been investigated. It is expected to be degraded into small peptides and amino acids via catabolic pathways in the same way as endogenous IgG
References
[1] Anthony V Serritella, Niraj K Shenoy. “Nivolumab Plus Ipilimumab vs Nivolumab Alone in Advanced Cancers Other Than Melanoma: A Meta-Analysis.” Jama Oncology (2023): 1441–1446.
[2] Jonathan Ho, C. Kelly, Erick A. Argueta. “S3644 Nivolumab-Induced Liver Injury.” American Journal of Gastroenterology (2021).
[3] Yang Wang. “Nivolumab combined docetaxel versus nivolumab in patients with previously treated nonsmall cell lung cancer: a phase 2 study.” Anti-Cancer Drugs (2024).
Nivolumab Preparation Products And Raw materials
Raw materials
Preparation Products
Nivolumab Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Shanghai Minbiotech Co., Ltd. | +8617315815539 | sales@minbiotech.com | CHINA | 129 | 58 |
| Nanjing Finetech Chemical Co., Ltd. | 025-85710122 17714198479 | sales@fine-chemtech.com | CHINA | 885 | 55 |
| Hubei xin bonus chemical co. LTD | 86-13657291602 | linda@hubeijusheng.com | CHINA | 22968 | 58 |
| BOC Sciences | +1-631-485-4226 | inquiry@bocsci.com | United States | 19553 | 58 |
| TopScience Biochemical | 00852-68527855 | info@itopbiochem.com | China Hong Kong | 902 | 58 |
| career henan chemical co | +86-0371-86658258 15093356674; | factory@coreychem.com | China | 29826 | 58 |
| Shaanxi Dideu Medichem Co. Ltd | +86-29-87569266 15319487004 | 1015@dideu.com | China | 2263 | 58 |
| Hubei Ipure Biology Co., Ltd | +8613367258412 | ada@ipurechemical.com | China | 10326 | 58 |
| HONG KONG IPURE BIOLOGY CO.,LIMITED | 86 18062405514 18062405514 | ada@ipurechemical.com | CHINA | 3465 | 58 |
| Dideu Industries Group Limited | +86-29-89586680 +86-15129568250 | 1026@dideu.com | China | 29474 | 58 |
View Lastest Price from Nivolumab manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2021-09-29 | Nivolumab
946414-94-4
|
US $0.00 / mg | 1mg | 99%~101% | 500g/month | WUHAN FORTUNA CHEMICAL CO., LTD | |
 |
2021-07-02 | Nivolumab USP/EP/BP
946414-94-4
|
US $1.10 / g | 1g | 99.9% | 100 Tons Min | Dideu Industries Group Limited | |
 |
2020-05-03 | Nivolumab
946414-94-4
|
US $0.00-0.00 / Kg | 1KG | 99.0% | 800 ton | Shaanxi Dideu Medichem Co. Ltd |
-
- Nivolumab
946414-94-4
- US $0.00 / mg
- 99%~101%
- WUHAN FORTUNA CHEMICAL CO., LTD
-
- Nivolumab USP/EP/BP
946414-94-4
- US $1.10 / g
- 99.9%
- Dideu Industries Group Limited
-
- Nivolumab
946414-94-4
- US $0.00-0.00 / Kg
- 99.0%
- Shaanxi Dideu Medichem Co. Ltd